Graftys, manufacturer of bone graft substitutes for orthopedic surgery, announces its acquisition of Biologics4Life, developer of a new generation of injectable synthetic bone graft materials. To achieve its new development and commercial ambitions, Graftys raised $3 million from Go Capital via its Ouest Venture 3 fund along with Noshaq and other European investors. This fundraising will be complemented with investment from Belgian, French and other European public subsidies.
Graftys manufactures a range of resorbable calcium phosphate cement. Its products are commercialized in over 25 countries (including the U.S. and Brazil) with clearance from FDA, CDMAS, Anvisa and the European notified body. Revenues in 2021 reached several million Euros.
Biologics4Life is an early-stage company committed to the design and development of advanced biomaterial technologies to treat bone metabolic disorders. Their focus has been on combination materials including active principles for the treatment of osteoporotic fractures and bone metastases.
Graftys’ acquisition of Biologics4Life will build its expertise in bone graft and in advanced treatment for patients suffering from fracture or bone loss. The combination will strengthen cross-functional capabilities in R&D, manufacturing, regulatory affairs, and global commercialization.